Evidence map›Paper›PMID 36135183›Full record

ArticleCurrent issues in molecular biology2022

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer.

Hongqin Zhang, Tianqing Yan, Ailing Zhong, Lin Guo, Renquan Lu

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hongqin ZhangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai 200032, China.
Tianqing YanDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai 200032, China.ORCID 0000-0003-3410-0395
Ailing ZhongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai 200032, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai 200032, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai 200032, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNQingdao University · CN

Funding

National Natural Science Foundation of China 81772774
6 · The paper itself

Abstract

Development of platinum resistance is one of the major causes of epithelial ovarian cancer (EOC) treatment failure. COP9 signalosome subunit 5 (COPS5) was found to take part in the progression of EOC in our previous study. Herein, we aim to uncover the potential utility of COPS5 in EOC chemoresistance. COPS5 levels were analyzed to define clinic pathologic correlates using a matched tissue microarray and online datasets. The effect of COPS5 inhibition by the lentivirus-mediated short hairpin RNA on cell viability, proliferation and migration was accessed in vitro and in vivo. Results showed that COPS5 was upregulated in patients after platinum resistance. Kaplan-Meier survival curves revealed that COPS5 overexpression was correlated with shorter PFS and OS. COPS5 downregulation inhibited the cell proliferation, migration, and reduced the sensitivity of EOC to platinum. Overall, our data indicated that COPS5 inhibition might represent a new therapeutic strategy for overcoming platinum resistance in patients with EOC.

Indexed as

COP9 signalosome subunit 5ovarian cancerplatinum resistance

Identifiers

PMID36135183
PMCPMC9498275
OpenAlexW4294151754

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.